Joel Beatty
Stock Analyst at Baird
(4.49)
# 310
Out of 5,005 analysts
199
Total ratings
48.75%
Success rate
27.65%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LRMR Larimar Therapeutics | Maintains: Outperform | $10 → $7 | $4.87 | +43.74% | 3 | Sep 30, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $50 → $67 | $34.94 | +91.76% | 3 | Sep 9, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $4 → $6 | $3.92 | +53.06% | 5 | Aug 13, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $7 → $9 | $15.76 | -42.89% | 6 | Jul 8, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $134.61 | +7.72% | 8 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $21.80 | +42.20% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $22.34 | +7.43% | 5 | May 16, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $800.00 | -15.00% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $15.42 | +88.07% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $65.37 | +0.96% | 15 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $167 → $155 | $139.48 | +11.13% | 4 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $120.30 | +34.66% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $31.06 | +32.00% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $12.56 | +27.39% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $11.35 | +40.97% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $54.38 | +34.24% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $20.84 | +53.55% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $53.26 | +40.82% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $13.42 | -18.03% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.86 | +276.34% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $55.43 | +17.27% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $31.21 | +130.70% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $540 → $240 | $1.60 | +14,900.00% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.35 | +233.33% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $9.38 | +166.52% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.53 | +1,586.97% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $15.60 | +79.49% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $2.08 | +669.23% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.75 | -28.57% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.52 | +2,794.74% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $36.12 | +60.58% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $27.64 | -13.17% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $22.56 | -20.21% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.19 | +173.97% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.73 | +388.66% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $456.35 | -61.65% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $5.43 | +157.83% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $22.64 | +377.03% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $69.15 | +12.80% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $12.90 | +675.19% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $18.84 | +536.94% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.48 | +12,831.03% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $3.30 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $9.46 | +58.56% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.62 | +19,109.22% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $9.57 | +98.54% | 3 | Nov 10, 2017 |
Larimar Therapeutics
Sep 30, 2025
Maintains: Outperform
Price Target: $10 → $7
Current: $4.87
Upside: +43.74%
Dianthus Therapeutics
Sep 9, 2025
Maintains: Outperform
Price Target: $50 → $67
Current: $34.94
Upside: +91.76%
Editas Medicine
Aug 13, 2025
Maintains: Outperform
Price Target: $4 → $6
Current: $3.92
Upside: +53.06%
Cogent Biosciences
Jul 8, 2025
Maintains: Neutral
Price Target: $7 → $9
Current: $15.76
Upside: -42.89%
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $134.61
Upside: +7.72%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $21.80
Upside: +42.20%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $22.34
Upside: +7.43%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $800.00
Upside: -15.00%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $15.42
Upside: +88.07%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $65.37
Upside: +0.96%
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $139.48
Upside: +11.13%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $120.30
Upside: +34.66%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $31.06
Upside: +32.00%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $12.56
Upside: +27.39%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $11.35
Upside: +40.97%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $54.38
Upside: +34.24%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $20.84
Upside: +53.55%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $53.26
Upside: +40.82%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $13.42
Upside: -18.03%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.86
Upside: +276.34%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $55.43
Upside: +17.27%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $31.21
Upside: +130.70%
May 15, 2024
Maintains: Outperform
Price Target: $540 → $240
Current: $1.60
Upside: +14,900.00%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.35
Upside: +233.33%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $9.38
Upside: +166.52%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.53
Upside: +1,586.97%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $15.60
Upside: +79.49%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $2.08
Upside: +669.23%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.75
Upside: -28.57%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.52
Upside: +2,794.74%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $36.12
Upside: +60.58%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $27.64
Upside: -13.17%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $22.56
Upside: -20.21%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.19
Upside: +173.97%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.73
Upside: +388.66%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $456.35
Upside: -61.65%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $5.43
Upside: +157.83%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $22.64
Upside: +377.03%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $69.15
Upside: +12.80%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $12.90
Upside: +675.19%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $18.84
Upside: +536.94%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.48
Upside: +12,831.03%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $3.30
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $9.46
Upside: +58.56%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.62
Upside: +19,109.22%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $9.57
Upside: +98.54%